Ipilimumab-Related Orbital Inflammation and Hypophysitis in Patients with Metastatic Melanoma: A Brief Case Series

Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 used for the treatment of metastatic melanoma. The most frequent adverse reactions associated with Ipilimumab have been autoimmune disorders, including enteritis, uveitis and arthritis. Myasthenia Gravis and hypophysitis have also been previously identified as potential adverse events, but orbital inflammation has not been well established as a potential adverse affect of this medication yet, with only one case previously described.